Clinical trials: Liver Carcinoma Resectable
Hepatocellular Carcinoma
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of…
- Trial name
- NCT06349317
- Testing
- Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Yongyi Zeng
Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
The goal of this clinical trial is to evaluate whether giving a single dose of Nivolumab (Opdivo®) before curative surgery for patients with resectable liver cancer can activate the body's immune response against the cancer and…
- Conditions
- Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant Therapy
- Trial name
- NCT07902258
- Testing
- Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Liver Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00093548
- Testing
- alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
- Sponsor
- Jonsson Comprehensive Cancer Center
HCC
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence.
- Trial name
- NCT06930573
- Testing
- AK112
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatocellular Carcinoma Resectable
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can…
- Trial name
- NCT06157060
- Testing
- circulating tumor DNA
- Where
- 7 sites in China
- Volunteers
- 255 people
- Sponsor
- Zhujiang Hospital
Hepatocellular Carcinoma Non-resectable
Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma
Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03564405
- Testing
- UNI-DEB
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma Non-resectable
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable…
- Trial name
- ExTRACT-HCC (NCT04965454)
- Testing
- Fluorine-18 fluorocholine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Queen's Medical Center
Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence
- Trial name
- NCT04701060
- Testing
- Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Potentially Resectable Hepatocellular Carcinoma
Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion
This study is a single-center, exploratory clinical trial. Eligible patients with liver cancer, after signing the informed consent form, will be screened and enrolled.
- Trial name
- HCC (NCT07738055)
- Testing
- Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital